Advaxis’ Preclinical Neoantigen Technology (ADXS-NEO)

Advaxis’ Preclinical Neoantigen Technology (ADXS-NEO)

AnnualMeeting2017

2 years
1,438 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and Advaxis that is designed to activate a patient's immune system to respond to certain mutations in the tumors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Up Next Autoplay